Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $19.5M | $27.9M | $50.9M | $23.4M | $7.00M | $219M |
| Revenue growth | — | — | — | — | 43.0% | 82.3% | -54.1% | -70.1% | 3024.4% |
| Operating income | -$14.4M | -$36.4M | -$44.3M | -$35.3M | -$50.3M | -$62.5M | -$134M | -$327M | -$159M |
| Operating margin | — | — | — | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Net income | -$11.9M | -$34.3M | -$42.0M | -$34.5M | -$49.8M | -$58.7M | -$113M | -$274M | -$114M |
| Net margin | — | — | — | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (diluted) | -$17.06 | -$35.92 | -$3.36 | -$1.40 | -$1.41 | -$1.42 | -$1.96 | -$3.36 | -$1.28 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.2M | -$27.6M | -$39.3M | $55.5M | -$55.8M | -$87.2M | -$115M | -$248M | -$71.1M |
| Capital expenditures | $1.76M | $1.71M | $1.35M | $493K | $2.64M | $3.44M | $2.37M | $3.86M | $2.37M |
| Free cash flow | -$14.0M | -$29.3M | -$40.7M | $55.0M | -$58.4M | -$90.6M | -$118M | -$251M | -$73.5M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.96M | $20.5M | $34.1M | $72.0M | $92.0M | $68.6M | $157M | $84.4M | $113M |
| Total assets | — | $96.5M | $113M | $298M | $381M | $388M | $649M | $1.12B | $1.11B |
| Total liabilities | — | $7.10M | $12.6M | $100.0M | $79.8M | $38.5M | $28.2M | $64.9M | $86.4M |
| Shareholders' equity | -$15.7M | -$48.9M | $100M | $198M | $302M | $349M | $621M | $1.06B | $1.02B |
| Retained earnings | — | -$50.5M | -$92.5M | -$127M | -$177M | -$235M | -$348M | -$623M | -$737M |
| Shares (wtd avg diluted) | — | 1.34M | 20.3M | 24.7M | 35.3M | 41.4M | 57.5M | 81.7M | 88.5M |
Every figure is extracted from IDEAYA Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.